Showing 5841-5850 of 5956 results for "".
- Eyenovia Appoints Michael Rowe as Vice President of Marketinghttps://modernod.com/news/eyenovia-appoints-michael-rowe-as-vice-president-of-marketing/2480038/Eyenovia announced the appointment of Michael Rowe as Vice President of Marketing. Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the United States and globally across the healthcare industry.
- MPOD Measurement Earns American Medical Association CPT III Codehttps://modernod.com/news/mpod-measurement-earns-american-medical-association-cpt-iii-code/2480039/EyePromise announced that on July 1, 2018, macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT Code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT Codes are used for da
- Katena Products Announces the Acquisition of Blink Medicalhttps://modernod.com/news/katena-products-announces-the-acquisition-of-blink-medical/2480044/Katena Products announced the purchase of Blink Medical, a UK-based provider of primarily single use ophthalmic instruments. Terms of the deal were not announced. Founded in 2004, Blink Medical currently distributes its products within Europe and the Middle East.
- Novartis Chairman Says Alcon Worth $20 Billion to $30 Billion: Finanz und Wirtschafthttps://modernod.com/news/novartis-chairman-says-alcon-worth-20-billion-30-billion-finanz-und-wirtschaft/2480052/The chairman of Swiss Novartis expects Alcon to be valued at between $20 billion and $30 billion when the ophthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft, according to a Reuters
- Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Diseasehttps://modernod.com/news/lin-bioscience-receives-ema-orphan-drug-status-for-lbs-008-for-the-treatment-of-stargardt-disease/2480056/Lin BioScience announced that the European Medicines Agency has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is currently an untreatable inherited condition that causes permanent vision loss in children
- Former P&G And Cincinnati Children’s Executive Katherine Overbey Joins OneSight As President And Executive Directorhttps://modernod.com/news/former-pg-and-cincinnati-childrens-executive-katherine-overbey-joins-onesight-as-president-and-executive-director/2480057/Global vision care nonprofit OneSight announced that Katherine “K-T” Overbey will be joining the organization as President and Executive Director. Ms. Overbey brings a distinct blend of blue-chip corporate and nonprofit experience in both developed and emerging markets, as well as a s
- Neuro-Optometric Rehabilitation Association (NORA) Launches Redesigned Website; Accepts Award Nominationshttps://modernod.com/news/neuro-optometric-rehabilitation-association-nora-launches-redesigned-website-accepts-award-nominations/2480061/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the launch of its redesigned website and new domain name, www.noravisionrehab.org, dedicated to educating patients, caregivers, and health care professionals about neurolog
- Market Scope: New Products Poised to Drive Glaucoma Pharma Market to $6.6 Billion by 2023https://modernod.com/news/market-scope-new-products-poised-to-drive-glaucoma-pharma-market-to-6-6-billion-by-2023/2480067/The launches of Vyzulta, Rhopressa, and preservative-free formulations promise to boost manufacturers’ revenues during the next 5 years in the global glaucoma pharmaceuticals market. The upswing follows years of declining revenues as branded products lost patent protection and the market s
- Staar Surgical and Kobe Kanagawa Eye Clinic in Japan Announce Strategic Cooperation Agreementhttps://modernod.com/news/staar-surgical-and-kobe-kanagawa-eye-clinic-in-japan-announce-strategic-cooperation-agreement/2480068/Staar Surgical and Kobe Kanagawa Eye Clinic, with locations in Tokyo and Osaka, announced they have entered into a multi-year Strategic Cooperation Agreement to provide Staar’s EVO Visian ICL lenses as a primary and premium option for patients seeking visual freedom from spectacles and cont
- Iridex Announces Multiple Studies of MicroPulse Laser Therapy Published at WOChttps://modernod.com/news/iridex-announces-multiple-studies-of-micropulse-laser-therapy-published-at-woc/2480069/Iridex announced new data was released at the World Ophthalmology Congress in Barcelona showing that MicroPulse Laser Therapy with the MicroPulse P3 Glaucoma Device is safe and effective. New real-world data shows a reduction in IOP close to 50%, with new morphological i